VERTEX PHARMACEUTICALS INC / MA VRTX
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
5/9
Piotroski F — financial health
7.5
Altman Z″ — distress risk · safe
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $12.0B | $4.0B | — | $3.2B | $18.7B |
| 2024 | $11.0B | -$535.6M | — | -$790.3M | $16.4B |
| 2023 | $9.9B | $3.6B | — | $3.3B | $17.6B |
| 2022 | $8.9B | $3.3B | — | $3.9B | $13.9B |
| 2021 | $7.6B | $2.3B | — | $2.4B | $10.1B |
| 2020 | $6.2B | $2.7B | — | $3.0B | $8.7B |
Why these scores methodology →
Piotroski F-score: 5/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: 7.5 (safe)
- Working capital / assets 0.286
- Retained earnings / assets 0.529
- EBIT / assets 0.163
- Equity / liabilities 2.675
Source: SEC EDGAR filings · CIK 0000875320 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.